AcelRx submits NDA to FDA for pain drug Zalviso
This article was originally published in Scrip
Executive Summary
AcelRx Pharmaceuticals wants the FDA's blessing to market Zalviso (sufentanil sublingual microtablet system) for moderate-to-severe acute pain in adults in the hospital setting.